What question did this study set out to answer?

Assess the use of continuous glucose monitoring in elderly patients with diabetes treated with intensive insulin therapy.

June 7, 2026

1905-P: Continuous Glucose Monitoring in Patients Aged ≥70 Years Ensures Safe and Effective Intensive Insulin Therapy

Key Points

Assess the use of continuous glucose monitoring in elderly patients with diabetes treated with intensive insulin therapy.
Retrospective observational study of patients aged ≥70 years with diabetes starting CGM after discharge, following education on its use.
Average one-year follow-up with CGM monitoring post-intensive insulin therapy.
Mean HbA1c decreased from 9.39% to 7.36% after 11.6 months of CGM usage (p<0.001).
Time in range (TIR) was 64.5%, time below range (TBR) was 1.5%, and time above range (TAR) was 34.0%.
Positive correlations observed between diabetes duration and coefficient of variation, as well as between coefficient of variation and TBR, and hypoglycemic episodes (all p<0.05).

Abstract

Introduction and Objective: Elderly individuals with diabetes are less likely to be offered continuous glucose monitoring (CGM), as they are often perceived as having difficulties using this technology. We conducted a retrospective observational study to assess the use of CGM in patients with diabetes aged ≥70 years. Methods: Patients aged ≥70 years with diabetes treated with intensive insulin therapy (IIT), hospitalized due to poor glycemic control, who started CGM (FreeStyle Libre 2) at discharge after CGM-oriented education, were included. CGM data were analyzed after an average follow-up of one year. Results: Fifty-eight inpatients (mean ±SD age 74.4±3.9 years; range 70-87 years; 21 women) with type 1 (n=10), type 2 (n=39), or diabetes associated with chronic pancreatitis (n=9), with diabetes duration of 20.2±14 years (range 1-50 years) and eGFR at admission of 60.9±20.4 ml/min/1.73 m², were included. Continuous intravenous insulin infusion and non-insulin antihyperglycemic agents were used during hospitalization. Mean HbA1c at admission was 9.39±2.92% (5.3-20.5%) and decreased to 7.36±0.86% (6.6-9.7%) after 11.6±8.3 months of continuing IIT and CGM use (p0.001). At the end of follow-up, time in range (TIR), time below range (70 mg/dl; TBR), and time above range (180 mg/dl; TAR) were 64.5±23.5%, 1.5±3.0%, and 34.0±23.6%, respectively. The coefficient of variation (CV) was 30.3±9.4%, sensor activity time 89±16%, number of daily scans 50.2±133.6 (range 2-951), and number of hypoglycemic episodes 0.2±0.3/day (0-1.3). No association was observed between age or diabetes duration and TIR, TBR, TAR, baseline HbA1c, or sensor activity time. A positive correlation was found between diabetes duration and CV (r=0.42), as well as between CV and TBR (r=0.71) and the number of hypoglycemic episodes (r=0.73; all p0.05). Conclusion: CGM should be recommended for patients aged ≥70 years treated with IIT, particularly those with longer diabetes duration, who are at increased risk of hypoglycemia. Disclosure M. Zarytowska: None. L. Czupryniak: Speaker's Bureau; Current; Abbott. Advisory Panel; Current; Abbott. Research Support; Current; Abbott.

Mark Helpful

Bookmark

Relay